OBIOOrchestra BioMed Holdings Inc
$4.02
$0.01
(0.25%)
Closed $4.02
$0.0308
(0.77%)
After Hours
Reported EarningsMay 12
Mkt Cap$241.32M
Vol288,739.00
Fundamentals
Mkt Cap
$241.32M
Volume
-
52W High
$5.42
52W Low
$2.20
PE Ratio
-3.56
Avg. Volume
260,008.39
EPS (Annual)
-$1.11
Rev/Employee
$389,325.58
Earnings
May 12
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +16.98% and -94.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Orchestra BioMed (OBIO) to Release Quarterly Earnings on Monday
Orchestra BioMed (NASDAQ:OBIO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-orchestra-biomed-holdings-inc-stock...
MarketBeat
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -55.00% and +3.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Growth in Short Interest
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling...
MarketBeat
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports...
MarketBeat
Orchestra BioMed (OBIO) to Release Earnings on Wednesday
Orchestra BioMed (NASDAQ:OBIO) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-1-orchestra-biomed-holdings-inc-stock...
MarketBeat
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold reco...
MarketBeat
HC Wainwright Has Optimistic Outlook of OBIO Q1 Earnings
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - HC Wainwright boosted their Q1 2026 earnings per share estimates for Orchestra BioMed in a report released on Monday, March 16th. HC...
MarketBeat
<
1
2
...
>